Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4

Purpose: The molecular features that account for the distinct histology and aggressive biological behavior of Gleason pattern 4 (Gp4) versus Gp3 prostate cancer, and whether Gp3 tumors progress directly to Gp4, remain to be established. Experimental Design: Whole-exome sequencing and transcriptome profiling of laser capture–microdissected adjacent Gp3 and cribiform Gp4 were used to determine the relationship between these entities. Results: Sequencing confirmed that adjacent Gp3 and Gp4 were clonal based on multiple shared genomic alterations. However, large numbers of unique mutations in the Gp3 and Gp4 tumors showed that the Gp4 were not derived directly from the Gp3. Remarkably, the Gp3 tumors retain their indolent-appearing morphology despite acquisition of multiple genomic alterations, including tumor suppressor losses. Although there were no consistent genomic alterations that distinguished Gp3 from Gp4, pairwise transcriptome analyses identified increased c-Myc and decreased p53 activity in Gp4 versus adjacent clonal Gp3 foci. Conclusions: These findings establish that at least a subset of Gp3 and aggressive Gp4 tumors have a common origin, and support a branched evolution model wherein the Gp3 and Gp4 tumors emerge early from a common precursor and subsequently undergo substantial divergence. Genomic alterations detectable in the Gp3 may distinguish these tumors from truly indolent Gp3. Screening for a panel of these genomic alterations in men who have prostate biopsies showing only Gp3 (Gleason score 6, Gs6) may allow for more precise selection of men who can be safely managed by active surveillance versus those who may benefit from further intervention. Clin Cancer Res; 23(14); 3823–33. ©2017 AACR.

[1]  F. Betsou,et al.  A Critical Evaluation of the PAXgene Tissue Fixation System:  Morphology, Immunohistochemistry, Molecular Biology, and Proteomics. , 2016, American journal of clinical pathology.

[2]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[3]  B. Trock,et al.  PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for Active Surveillance , 2016, Modern Pathology.

[4]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[5]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[6]  Faraz Hach,et al.  Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.

[7]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[8]  Trevor J Pugh,et al.  Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.

[9]  Matthew N Davies,et al.  Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale , 2015, Current opinion in genetics & development.

[10]  Andrew Menzies,et al.  Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.

[11]  S. Srivastava,et al.  A long noncoding RNA connects c-Myc to tumor metabolism , 2014, Proceedings of the National Academy of Sciences.

[12]  M. Loda,et al.  Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors , 2014, Clinical Cancer Research.

[13]  J. Squire,et al.  Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. , 2014, Cancer genetics.

[14]  Christopher D. Brown,et al.  Low-grade prostate cancer diverges early from high grade and metastatic disease , 2014, Cancer science.

[15]  A. Haese*,et al.  A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy. , 2014, The Journal of urology.

[16]  J. Hicks,et al.  PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy , 2014, Modern Pathology.

[17]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[18]  D. Watson,et al.  Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.

[19]  Sarah H. Johnson,et al.  Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. , 2013, Cancer research.

[20]  G. Bubley,et al.  Clonal progression of prostate cancers from Gleason grade 3 to grade 4. , 2013, Cancer Research.

[21]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[22]  Stephen R. Piccolo,et al.  A single-sample microarray normalization method to facilitate personalized-medicine workflows. , 2012, Genomics.

[23]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[24]  B. Trock,et al.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.

[25]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[26]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.

[27]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[28]  Stephen J. Salipante,et al.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.

[29]  Matthew R Cooperberg,et al.  Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Kattan,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[31]  A. Partin,et al.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[33]  C. Bieberich,et al.  MYC and Prostate Cancer. , 2010, Genes & cancer.

[34]  M. Rubin,et al.  Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort , 2009, Modern Pathology.

[35]  Y. Nakatani,et al.  Molecular analysis of multifocal prostate cancer by comparative genomic hybridization , 2008, The Prostate.

[36]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[37]  J. Epstein,et al.  Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. , 2008, The Journal of urology.

[38]  J. Paramio,et al.  Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. , 2008, Cancer research.

[39]  M. Rubin,et al.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. , 2007, Urology.

[40]  Andrej Lupták,et al.  A Genomewide Search for Ribozymes Reveals an HDV-Like Sequence in the Human CPEB3 Gene , 2006, Science.

[41]  Leroy Hood,et al.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[43]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[44]  J. Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[45]  Kathryn A. O’Donnell,et al.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.

[46]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[47]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[48]  P. Walsh,et al.  Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. , 2001, The Journal of urology.

[49]  D. Bostwick,et al.  Allelic imbalance in the clonal evolution of prostate carcinoma , 1999, Cancer.

[50]  D. Stéhelin,et al.  Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains , 1998, Oncogene.

[51]  L. Liotta,et al.  Evidence of Independent Origin of Multiple Tumors From Patients With Prostate Cancer , 1998 .

[52]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  小林 将行 Molecular analysis of multifocal prostate cancer by comparative genomic hybridization , 2009 .

[54]  W. Liang,et al.  9) TM4 Microarray Software Suite , 2006 .

[55]  L. Liotta,et al.  Evidence of independent origin of multiple tumors from patients with prostate cancer. , 1998, Journal of the National Cancer Institute.

[56]  N. Maitland,et al.  Precise microdissection of human prostate cancers reveals genotypic heterogeneity. , 1998, Cancer research.